Anthracyclines in the treatment of patients with early breast cancer

In the past decades, systemic treatment for early-stage breast cancer (EBC) patients has undergone a profound evolution, driven by the progressively improving knowledge and understanding of breast tumor biology, with consequent outcome improvement. In this context, chemotherapy still represents a cornerstone of EBC treatment across different breast cancer (BC) subtypes. Once chemotherapy is considered, the next step is a careful risk–benefit balance aiming at choosing which specific regimen to offer.